BARCELONA, Spain, Oct. 5, 2025 /PRNewswire/ -- High metabolic activity of visceral fat may be associated with more aggressive endometrial cancer, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has shown. While obesity is a recognised risk factor for endometrial cancer, the findings indicate that disease aggressiveness may be driven not only by the amount of visceral fat but also by its metabolic activity. Visceral fat is the fa

Partnership Expands Access to Next-Generation Minimally Invasive Solution for Surgical Evacuation of Intracerebral Hemorrhage. SAN JOSE, Calif., Oct. 3, 2025 /PRNewswire/ -- Clearmind Biomedical, a leader in minimally invasive neurosurgical innovation, today announced it has signed an exclusive U.S. distribution agreement with Sutter Medical for the Neuroblade Multi-Function Neuro-Endoscope System, a 510(k)-cleared device engineered to advance the treatment of complex neurosurgical conditions

PHILADELPHIA, Oct. 3, 2025 /PRNewswire/ -- LEGAL NOTICE If You Paid or Reimbursed for Certain PRESCRIPTION GENERIC DRUGS in the United States between May 1, 2009 and December 31, 2019, You Could Get a Payment from a Class Action Settlement. A federal court authorized this Notice. This is not a solicitation from a lawyer. 1-877-316-0171 Your legal rights might be affected by a new $200 million Settlement with Sun Pharmaceutical Industries, Inc. ("Sun") and Taro Pharmaceuticals U.S.A., Inc.

JERSEY CITY, N.J., Oct. 3, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced today it has entered into warrant exercise agreements with certain existing accredited and institutional investors to exercise outstanding warrants to purchase an aggr

MADISON, Wis., Oct. 3, 2025 /PRNewswire/ -- Leo Cancer Care announced that it has placed orders for TibaRay's advanced linear accelerators (linacs), which will be evaluated as an upgrade option to the company's Grace photon therapy platform, currently in research and development. The integration of TibaRay's high-efficiency linac technology will be studied as part of Grace's development program. TibaRay's accelerators are designed to deliver higher dose rates than conventional systems, opening t

ProSense ® cryoablation offers the choice of a minimally invasive outpatient procedure that destroys tumors by freezing without surgical removal of breast tissue First new innovation in the local treatment of early-stage, low-risk breast cancer in decades and only medical device to be granted FDA marketing authorization for breast cancer treatment Offers efficacy and safety similar to standard of care lumpectomy, with excellent cosmetic results and patient satisfaction Com

ProSense® is the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer Major advancement and new paradigm in breast cancer care as a simple, minimally invasive out-patient procedure Initial reimbursement under the CPT III code which covers $3,800 of facility costs, with additional reimbursement coverage expected U.S. sales and distribution team ready to drive sales of ProSense® systems and disposable probes—supporting medical

- Designation sets the stage for intensive phase III trial planning with FDA - NEWARK, Del., Oct. 3, 2025 /PRNewswire/ -- Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that the U.S. Food and Drug Administration ("FDA") has granted Regenerative Medicine Advanced Therapy ("RMAT") designation for AVB-114, the Company's lead therapeutic candidate for Crohn's perianal fistulas. Building upon its existing Fast Track Designation for AVB-114, RMAT design

BridgeBio has been quietly building a sprawling pipeline at its private spinout GondolaBio. The rare disease startup launched last year with a few of BridgeBio’s rare disease assets and $300 million in funding commitments from investors such as Viking and Patient Square Capital. BridgeBio owns about 29% of GondolaBio, according to an August presentation . Over the course of this year, GondolaBio’s pipeline has grown to 17 assets, a size almost unheard of in today’s private biotech landscape. Inv

The National Comprehensive Cancer Network guidelines added Tecentriq-Zepzelca maintenance as a preferred regimen in first-line extensive stage small cell lung cancer a few days before the FDA approval. An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer.The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s Tecentriq, as a first-line maintenance treatment in extensive-stage small cell lung cancer (ES-SCL